responsibility of the receiving entity and indicates a violation or potential violation of law;

2. A court, magistrate, grand jury, or administrative tribunal in the course of presenting evidence, including disclosures to opposing counsel or witnesses in the course of civil discovery, litigation, or settlement negotiations in response to a court-ordered subpoena or in connection with criminal, civil, or regulatory proceedings;

3. A Member of Congress or a congressional office in order for that Member or office to respond to communications from the participant who is the subject of the record;

4. The Department of Justice for the purpose of further investigation and prosecution;

5. The current or former employing agency of the participant for the purpose of further investigation and administrative action;

6. Informants, complainants, or victims to the extent necessary to provide those persons with information and explanations concerning the progress or results of the investigation; and

7. A Federal, foreign, state, or local agency or a person or entity if necessary to obtain information relevant to the investigation of the allegations or prosecution of the case.

POLICIES AND PRACTICES FOR STORING, RETRIEVING, ACCESSING, RETAINING, AND DISPOSING OF RECORDS IN THE SYSTEM:

STORAGE:

These records are maintained in file folders in office file cabinets and on electronic media or computer in the system location.

RETRIEVABILITY:

These records are indexed by the names and Social Security numbers of Thrift Savings Plan participants.

SAFEGUARDS:

Access to and use of these records is restricted to those persons whose official duties require such access.

RETENTION AND DISPOSAL:

Records in this system are destroyed seven years after the case is closed.

SYSTEM MANAGER(S) AND ADDRESS:

Director, Office of Benefits and Program Analysis, Federal Retirement Thrift Investment Board, 1250 H Street, NW, Washington, DC 20005.

NOTIFICATION PROCEDURE:

Inquiries under the Privacy Act of 1974 should be addressed to the Privacy Act Officer, Federal Retirement Thrift Investment Board, 1250 H Street, NW, Washington, DC 20005. All individuals making inquiries should provide with their request as much descriptive matter as is possible to identify the particular record desired.

RECORD ACCESS PROCEDURES:

Individuals requesting information under the Privacy Act of 1974 concerning procedures for gaining access or contesting records should write to the Privacy Act Officer. All individuals are urged to examine the regulations at 5 CFR part 1630 concerning Board requirements with respect to the Privacy Act of 1974.

CONTESTING RECORD PROCEDURES:

See ''Record Access Procedures'' above.

RECORD SOURCE CATEGORIES:

Records in this system may be provided by or obtained from the following: Persons to whom the information relates when practicable, including Thrift Savings Plan participants, complainants, informants, witnesses, investigators, and persons reviewing the allegations; Federal, state and local agencies; and investigative reports and records.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:

Pursuant to 5 U.S.C. 552a(k)(2) of the Privacy Act and the Board's regulation at 5 CFR 1630.10, certain portions of records under this system may be exempted from the provisions of the Privacy Act when: (1) Such portions represent investigatory materials compiled for law enforcement purposes or (2) such portions would reveal the identity of a source who furnished information to the Government under a promise of confidentiality which information resulted in the denial of a right, privilege, or benefit to a participant.

[FR Doc. 97–24762 Filed 9–17–97; 8:45 am]

BILLING CODE 6760–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services announces the following advisory committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS), Subcommittee on Population-Specific Issues.

Times and Dates: 10:00 a.m.–5:00 p.m., September 29, 1997; 9:00 a.m.–3:00 p.m., September 30, 1997.

Place: Room 303–339A, Hubert H. Humphrey Building, 200 Independence Avenue S.W., Washington D.C. 20201.

Status: Open.

Purpose: The Subcommittee plans to continue its exploration of data issues associated with Medicaid managed care. On September 29, presentations are scheduled from selected governmental agencies and private researchers on Medicaid managed care. On September 30, the Subcommittee will refine its work plan, identify tasks and resources, and establish time frames to complete its work.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from James Scanlon, NCVHS Executive Staff Director, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 440–D. Humphrey Building, 200 Independence Avenue S.W., Washington, D.C. 20201, telephone (202) 690–7100, or Marjorie S. Greenberg, Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436–7050. Additional information about the full Committee and the tentative agenda for the Subcommittee meeting is available on the NCVHS website: http://aspe.os.dhhs.gov/ncvhs

Dated: September 12, 1997.

James Scanlon,

Director, Division of Data Policy.

[FR Doc. 97–24763 Filed 9–17–97; 8:45 am]

BILLING CODE 4151–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Christopher Leonhard, Dartmouth College: Based upon an investigation conducted by Dartmouth College, information obtained by the Office of Research Integrity (ORI) during its oversight review, and Mr. Leonhard's own admission, ORI found that Mr. Leonhard, a former graduate student in the Department of Psychology, Dartmouth College, engaged in scientific misconduct arising out of certain biomedical research supported by two grants from the National Institute of Mental Health (NIMH), National Institutes of Health (NIH).

Specifically, Mr. Leonhard (1) fabricated experimental records and falsely represented them to his supervisor as being results obtained from multiple electrophysiological screening sessions conducted on eight animals; and (2) fabricated two surgical records as evidence of experimental preparations (implantation of indwelling electrodes) on two animals, which in fact had not been done. The experimental records did not appear in any publications.

Mr. Leonhard has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning September 8, 1997:

(1) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which Mr. Leonhard's participation is proposed or which uses him in any capacity on PHS supported research or that submits a report of PHS-funded research in which he is involved must concurrently submit a plan for supervision of his duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Mr. Leonhard's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–24808 Filed 9–17–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Biological Response Modifiers Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 17, 1997, 8 a.m. to 5:30 p.m.

Location: Holiday Inn, Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Gail M. Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting.

Agenda: During the morning session, the committee will discuss Zenapax®, (daclixiamab, a humanized monoclonal antibody directed against the human interleukin 2 receptor), Hoffmann-La Roche. An indication is sought for the prophylaxis of acute organ rejection as part of an immunosuppressive regimen for patients receiving cadaveric kidney transplants. During the afternoon session, the committee will discuss Intron-A®, (recombinant human interferon, interferon alfa–2b), Schering-Plough Corp. An indication is sought for the treatment of patients with high-tumor burden, follicular non-Hodgkin's lymphoma, in conjunction with combination chemotherapy.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 10, 1997. Oral presentations from the public will be scheduled between approximately 8 a.m. to 8:30 a.m., and 1 p.m. to 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 10, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

Dated: September 9, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–24849 Filed 9–17–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 23, 1997, 8:30 a.m. to 5:30 p.m., and October 24, 1997, 9 a.m. to 4 p.m.

Location: National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD.

Parking in the Clinical Center visitor area is reserved for Clinical Center patients and their visitors. If you must drive, please use an outlying lot such as Lot 41B. Free shuttle bus service is provided from Lot 41B to the Clinical Center every 8 minutes during rush hour and every 15 minutes at other times.

Contact Person: Joan C. Standaert, Center for Drug Evaluation and Research (HFD–110), 419–259–6211, or Danyiel D'Antonio (HFD–21), 301–443–5455, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 23, 1997, the committee will discuss basic statistical considerations for the evaluation of active control clinical trials, and new drug application (NDA) 20–845, inhaled nitric oxide (Ohmeda Pharmaceutical Products Division, Inc.), for treatment of primary pulmonary hypertension of the newborn. On October 24, 1997, the committee will discuss NDA 20–839, Plavix™ (clopidogrel bisulfate, Sanofi